RightFit Trial Directory

Leukemia clinical trials in Seattle, WA

41 recruiting leukemia studies with a site in Seattle, WA.

All trials in Seattle, WA · All Leukemia trials

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor: Alliance for Clinical Trials in Oncology

Aberdeen, WA · Bellevue, WA · Bellingham, WA · +452 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Seattle, WA · Spokane, WA · +113 more sites

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Edmonds, WA · Issaquah, WA · Seattle, WA · +172 more sites

RecruitingPhase 1NCT06528301

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Sponsor: Umoja Biopharma

Seattle, WA · +6 more sites

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Edmonds, WA · Issaquah, WA · Seattle, WA · +222 more sites

RecruitingPhase 3NCT06136559

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Sponsor: Merck Sharp & Dohme LLC

Edmonds, WA · Issaquah, WA · Seattle, WA · +46 more sites

RecruitingPhase 1 / Phase 2NCT06137118

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Sponsor: AstraZeneca

Seattle, WA · +11 more sites

RecruitingPhase 2NCT06672146

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Edmonds, WA · Issaquah, WA · Seattle, WA · +132 more sites

RecruitingPhase 1NCT03802695

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Sponsor: Orca Biosystems, Inc.

Seattle, WA · +11 more sites

RecruitingPhase 2NCT06514794

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Sponsor: Allotera Therapeutics

Seattle, WA · +15 more sites

RecruitingPhase 3NCT07277231

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Sponsor: BeOne Medicines

Seattle, WA · +21 more sites

RecruitingPhase 3NCT06852222

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Sponsor: Janssen Research & Development, LLC

Seattle, WA · +57 more sites

RecruitingPhase 3NCT04293562

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Sponsor: Children's Oncology Group

Seattle, WA · Spokane, WA · Tacoma, WA · +183 more sites

RecruitingPhase 1NCT04375631

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingNot applicableNCT07094750

Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingPhase 2NCT07221500

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Sponsor: Nurix Therapeutics, Inc.

Seattle, WA · +26 more sites

RecruitingPhase 2NCT07194980

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingNot applicableNCT07616921

A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant

Sponsor: University of Washington

Seattle, WA

RecruitingPhase 1 / Phase 2NCT04726241

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Sponsor: PedAL BCU, LLC

Seattle, WA · Spokane, WA · Tacoma, WA · +161 more sites

RecruitingPhase not listedNCT05702645

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

Sponsor: Children's Oncology Group

Seattle, WA · Spokane, WA · +70 more sites

RecruitingPhase 1NCT06247787

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Sponsor: Children's Oncology Group

Seattle, WA · +18 more sites

RecruitingPhase 1NCT06001788

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Sponsor: Kura Oncology, Inc.

Seattle, WA · +37 more sites

RecruitingPhase 2NCT03737955

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Sponsor: University of Washington

Seattle, WA

RecruitingPhase 2NCT07224100

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Sponsor: University of Washington

Seattle, WA

RecruitingPhase 2NCT06013423

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingPhase 2NCT07046078

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingNot applicableNCT06102330

Multicenter HomeVENT: Home Values and Experiences Navigation Track

Sponsor: Johns Hopkins University

Seattle, WA · +3 more sites

RecruitingPhase 1 / Phase 2NCT03670966

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingPhase not listedNCT05430971

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Sponsor: Immune Oncology Research Institute

Seattle, WA · +2 more sites

RecruitingPhase not listedNCT05865301

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

Sponsor: Stanford University

Seattle, WA · +21 more sites

RecruitingPhase 2NCT04195633

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingPhase not listedNCT01790152

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Sponsor: Children's Oncology Group

Seattle, WA · Spokane, WA · +67 more sites

RecruitingPhase 1 / Phase 2NCT06928662

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingPhase 2NCT03970096

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA · +2 more sites

RecruitingPhase 4NCT06876649

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Sponsor: Eli Lilly and Company

Seattle, WA · +19 more sites

RecruitingPhase 2NCT02143830

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Sponsor: Children's Hospital Medical Center, Cincinnati

Seattle, WA · +2 more sites

RecruitingNot applicableNCT06472128

Novel Digital Application for Patients With Acute Leukemia

Sponsor: Massachusetts General Hospital

Seattle, WA · +2 more sites

RecruitingPhase 1NCT05780034

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Sponsor: Accutar Biotechnology Inc

Seattle, WA · +8 more sites

RecruitingPhase 1NCT06501196

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Sponsor: BlossomHill Therapeutics

Seattle, WA · +12 more sites

RecruitingPhase 1NCT06462365

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Sponsor: Tr1X, Inc.

Seattle, WA · +4 more sites

Not yet recruitingPhase 2NCT07819396

Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.